 | • レポートコード：GIR-107A14625 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品 |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、がんmTOR阻害剤のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。がんmTOR阻害剤の種類別市場規模（アフィニトール/エベロリムス、トリセル（テムシロリムス）、エバーター）、用途別市場規模（乳がん、血液悪性腫瘍、神経内分泌腫瘍、肝細胞がん、膠芽腫）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・がんmTOR阻害剤の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Abraxis BioScience、Adimab、Celgene Corporation、Celator Pharmaceuticals、Eli Lilly、Exelixis、GlaxoSmithKline、HEC Pharm、Intellikine、Novartis、Oneness Biotech、PIQUR Therapeutics、Semafore Pharmaceuticals、Takeda、Wyeth ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：アフィニトール/エベロリムス、トリセル（テムシロリムス）、エバーター ・用途別分析2016年-2026年：乳がん、血液悪性腫瘍、神経内分泌腫瘍、肝細胞がん、膠芽腫 ・がんmTOR阻害剤の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・がんmTOR阻害剤のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・がんmTOR阻害剤のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・がんmTOR阻害剤の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・がんmTOR阻害剤の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Cancer mTOR Inhibitors market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Cancer mTOR Inhibitors size is estimated to be xx million in 2021 from USD xx million in 2020, with a change of XX% between 2020 and 2021. The global Cancer mTOR Inhibitors market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Cancer mTOR Inhibitors market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Afinitor/Votubia
Afinitor Disperz and ndash; mTOR inhibitor for Rare Pediatric Brain Tumor
Torisel (Temsirolimus)
Evertor andndash
Market segment by Application can be divided into
Breast Cancer
Hematological Malignancy
Neuroendocrine Tumors
Hepatocellular Carcinoma
Glioblastoma
The key market players for global Cancer mTOR Inhibitors market are listed below:
Abraxis BioScience
Adimab
Celgene Corporation
Celator Pharmaceuticals
Eli Lilly
Exelixis
GlaxoSmithKline
HEC Pharm
Intellikine
Novartis
Oneness Biotech
PIQUR Therapeutics
Semafore Pharmaceuticals
Takeda
Wyeth
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Cancer mTOR Inhibitors product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Cancer mTOR Inhibitors, with price, sales, revenue and global market share of Cancer mTOR Inhibitors from 2019 to 2021.
Chapter 3, the Cancer mTOR Inhibitors competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Cancer mTOR Inhibitors breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2026.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2026.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Cancer mTOR Inhibitors market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Cancer mTOR Inhibitors sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Cancer mTOR Inhibitors Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Cancer mTOR Inhibitors Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Afinitor/Votubia
1.2.3 Afinitor Disperz and ndash; mTOR inhibitor for Rare Pediatric Brain Tumor
1.2.4 Torisel (Temsirolimus)
1.2.5 Evertor andndash
1.3 Market Analysis by Application
1.3.1 Overview: Global Cancer mTOR Inhibitors Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Breast Cancer
1.3.3 Hematological Malignancy
1.3.4 Neuroendocrine Tumors
1.3.5 Hepatocellular Carcinoma
1.3.6 Glioblastoma
1.4 Global Cancer mTOR Inhibitors Market Size & Forecast
1.4.1 Global Cancer mTOR Inhibitors Sales in Value (2016-2026))
1.4.2 Global Cancer mTOR Inhibitors Sales in Volume (2016-2026)
1.4.3 Global Cancer mTOR Inhibitors Price by Type (2016-2026) & (USD/Pcs)
1.5 Global Cancer mTOR Inhibitors Production Capacity Analysis
1.5.1 Global Cancer mTOR Inhibitors Total Production Capacity (2016-2026)
1.5.2 Global Cancer mTOR Inhibitors Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Cancer mTOR Inhibitors Market Drivers
1.6.2 Cancer mTOR Inhibitors Market Restraints
1.6.3 Cancer mTOR Inhibitors Trends Analysis
2 Manufacturers Profiles
2.1 Abraxis BioScience
2.1.1 Abraxis BioScience Details
2.1.2 Abraxis BioScience Major Business
2.1.3 Abraxis BioScience Cancer mTOR Inhibitors Product and Services
2.1.4 Abraxis BioScience Cancer mTOR Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 Adimab
2.2.1 Adimab Details
2.2.2 Adimab Major Business
2.2.3 Adimab Cancer mTOR Inhibitors Product and Services
2.2.4 Adimab Cancer mTOR Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 Celgene Corporation
2.3.1 Celgene Corporation Details
2.3.2 Celgene Corporation Major Business
2.3.3 Celgene Corporation Cancer mTOR Inhibitors Product and Services
2.3.4 Celgene Corporation Cancer mTOR Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 Celator Pharmaceuticals
2.4.1 Celator Pharmaceuticals Details
2.4.2 Celator Pharmaceuticals Major Business
2.4.3 Celator Pharmaceuticals Cancer mTOR Inhibitors Product and Services
2.4.4 Celator Pharmaceuticals Cancer mTOR Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Eli Lilly
2.5.1 Eli Lilly Details
2.5.2 Eli Lilly Major Business
2.5.3 Eli Lilly Cancer mTOR Inhibitors Product and Services
2.5.4 Eli Lilly Cancer mTOR Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Exelixis
2.6.1 Exelixis Details
2.6.2 Exelixis Major Business
2.6.3 Exelixis Cancer mTOR Inhibitors Product and Services
2.6.4 Exelixis Cancer mTOR Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.7 GlaxoSmithKline
2.7.1 GlaxoSmithKline Details
2.7.2 GlaxoSmithKline Major Business
2.7.3 GlaxoSmithKline Cancer mTOR Inhibitors Product and Services
2.7.4 GlaxoSmithKline Cancer mTOR Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.8 HEC Pharm
2.8.1 HEC Pharm Details
2.8.2 HEC Pharm Major Business
2.8.3 HEC Pharm Cancer mTOR Inhibitors Product and Services
2.8.4 HEC Pharm Cancer mTOR Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.9 Intellikine
2.9.1 Intellikine Details
2.9.2 Intellikine Major Business
2.9.3 Intellikine Cancer mTOR Inhibitors Product and Services
2.9.4 Intellikine Cancer mTOR Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.10 Novartis
2.10.1 Novartis Details
2.10.2 Novartis Major Business
2.10.3 Novartis Cancer mTOR Inhibitors Product and Services
2.10.4 Novartis Cancer mTOR Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.11 Oneness Biotech
2.11.1 Oneness Biotech Details
2.11.2 Oneness Biotech Major Business
2.11.3 Oneness Biotech Cancer mTOR Inhibitors Product and Services
2.11.4 Oneness Biotech Cancer mTOR Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.12 PIQUR Therapeutics
2.12.1 PIQUR Therapeutics Details
2.12.2 PIQUR Therapeutics Major Business
2.12.3 PIQUR Therapeutics Cancer mTOR Inhibitors Product and Services
2.12.4 PIQUR Therapeutics Cancer mTOR Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.13 Semafore Pharmaceuticals
2.13.1 Semafore Pharmaceuticals Details
2.13.2 Semafore Pharmaceuticals Major Business
2.13.3 Semafore Pharmaceuticals Cancer mTOR Inhibitors Product and Services
2.13.4 Semafore Pharmaceuticals Cancer mTOR Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.14 Takeda
2.14.1 Takeda Details
2.14.2 Takeda Major Business
2.14.3 Takeda Cancer mTOR Inhibitors Product and Services
2.14.4 Takeda Cancer mTOR Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.15 Wyeth
2.15.1 Wyeth Details
2.15.2 Wyeth Major Business
2.15.3 Wyeth Cancer mTOR Inhibitors Product and Services
2.15.4 Wyeth Cancer mTOR Inhibitors Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Cancer mTOR Inhibitors Sales by Manufacturer
3.1 Global Cancer mTOR Inhibitors Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Cancer mTOR Inhibitors Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Cancer mTOR Inhibitors
3.4 Market Concentration Rate
3.4.1 Top 3 Cancer mTOR Inhibitors Manufacturer Market Share
3.4.2 Top 6 Cancer mTOR Inhibitors Manufacturer Market Share
3.5 Global Cancer mTOR Inhibitors Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Cancer mTOR Inhibitors Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Cancer mTOR Inhibitors Market Size by Region
4.1.1 Global Cancer mTOR Inhibitors Sales in Volume by Region (2016-2026)
4.1.2 Global Cancer mTOR Inhibitors Revenue by Region (2016-2026)
4.2 North America Cancer mTOR Inhibitors Revenue (2016-2026)
4.3 Europe Cancer mTOR Inhibitors Revenue (2016-2026)
4.4 Asia-Pacific Cancer mTOR Inhibitors Revenue (2016-2026)
4.5 South America Cancer mTOR Inhibitors Revenue (2016-2026)
4.6 Middle East and Africa Cancer mTOR Inhibitors Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Cancer mTOR Inhibitors Sales in Volume by Type (2016-2026)
5.2 Global Cancer mTOR Inhibitors Revenue by Type (2016-2026)
5.3 Global Cancer mTOR Inhibitors Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Cancer mTOR Inhibitors Sales in Volume by Application (2016-2026)
6.2 Global Cancer mTOR Inhibitors Revenue by Application (2016-2026)
6.3 Global Cancer mTOR Inhibitors Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Cancer mTOR Inhibitors Sales by Type (2016-2026)
7.2 North America Cancer mTOR Inhibitors Sales by Application (2016-2026)
7.3 North America Cancer mTOR Inhibitors Market Size by Country
7.3.1 North America Cancer mTOR Inhibitors Sales in Volume by Country (2016-2026)
7.3.2 North America Cancer mTOR Inhibitors Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Cancer mTOR Inhibitors Sales by Type (2016-2026)
8.2 Europe Cancer mTOR Inhibitors Sales by Application (2016-2026)
8.3 Europe Cancer mTOR Inhibitors Market Size by Country
8.3.1 Europe Cancer mTOR Inhibitors Sales in Volume by Country (2016-2026)
8.3.2 Europe Cancer mTOR Inhibitors Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Cancer mTOR Inhibitors Sales by Type (2016-2026)
9.2 Asia-Pacific Cancer mTOR Inhibitors Sales by Application (2016-2026)
9.3 Asia-Pacific Cancer mTOR Inhibitors Market Size by Region
9.3.1 Asia-Pacific Cancer mTOR Inhibitors Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Cancer mTOR Inhibitors Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Cancer mTOR Inhibitors Sales by Type (2016-2026)
10.2 South America Cancer mTOR Inhibitors Sales by Application (2016-2026)
10.3 South America Cancer mTOR Inhibitors Market Size by Country
10.3.1 South America Cancer mTOR Inhibitors Sales in Volume by Country (2016-2026)
10.3.2 South America Cancer mTOR Inhibitors Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Cancer mTOR Inhibitors Sales by Type (2016-2026)
11.2 Middle East & Africa Cancer mTOR Inhibitors Sales by Application (2016-2026)
11.3 Middle East & Africa Cancer mTOR Inhibitors Market Size by Country
11.3.1 Middle East & Africa Cancer mTOR Inhibitors Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Cancer mTOR Inhibitors Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Cancer mTOR Inhibitors Typical Distributors
12.3 Cancer mTOR Inhibitors Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Cancer mTOR Inhibitors Revenue by Type, (USD Million), 2021-2026
Table 2. Global Cancer mTOR Inhibitors Revenue by Application, (USD Million), 2021-2026
Table 3. Abraxis BioScience Basic Information, Manufacturing Base and Competitors
Table 4. Abraxis BioScience Major Business
Table 5. Abraxis BioScience Cancer mTOR Inhibitors Product and Services
Table 6. Abraxis BioScience Cancer mTOR Inhibitors Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Adimab Basic Information, Manufacturing Base and Competitors
Table 8. Adimab Major Business
Table 9. Adimab Cancer mTOR Inhibitors Product and Services
Table 10. Adimab Cancer mTOR Inhibitors Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Celgene Corporation Basic Information, Manufacturing Base and Competitors
Table 12. Celgene Corporation Major Business
Table 13. Celgene Corporation Cancer mTOR Inhibitors Product and Services
Table 14. Celgene Corporation Cancer mTOR Inhibitors Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Celator Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 16. Celator Pharmaceuticals Major Business
Table 17. Celator Pharmaceuticals Cancer mTOR Inhibitors Product and Services
Table 18. Celator Pharmaceuticals Cancer mTOR Inhibitors Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 20. Eli Lilly Major Business
Table 21. Eli Lilly Cancer mTOR Inhibitors Product and Services
Table 22. Eli Lilly Cancer mTOR Inhibitors Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Exelixis Basic Information, Manufacturing Base and Competitors
Table 24. Exelixis Major Business
Table 25. Exelixis Cancer mTOR Inhibitors Product and Services
Table 26. Exelixis Cancer mTOR Inhibitors Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 28. GlaxoSmithKline Major Business
Table 29. GlaxoSmithKline Cancer mTOR Inhibitors Product and Services
Table 30. GlaxoSmithKline Cancer mTOR Inhibitors Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. HEC Pharm Basic Information, Manufacturing Base and Competitors
Table 32. HEC Pharm Major Business
Table 33. HEC Pharm Cancer mTOR Inhibitors Product and Services
Table 34. HEC Pharm Cancer mTOR Inhibitors Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Intellikine Basic Information, Manufacturing Base and Competitors
Table 36. Intellikine Major Business
Table 37. Intellikine Cancer mTOR Inhibitors Product and Services
Table 38. Intellikine Cancer mTOR Inhibitors Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 39. Novartis Basic Information, Manufacturing Base and Competitors
Table 40. Novartis Major Business
Table 41. Novartis Cancer mTOR Inhibitors Product and Services
Table 42. Novartis Cancer mTOR Inhibitors Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 43. Oneness Biotech Basic Information, Manufacturing Base and Competitors
Table 44. Oneness Biotech Major Business
Table 45. Oneness Biotech Cancer mTOR Inhibitors Product and Services
Table 46. Oneness Biotech Cancer mTOR Inhibitors Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 47. PIQUR Therapeutics Basic Information, Manufacturing Base and Competitors
Table 48. PIQUR Therapeutics Major Business
Table 49. PIQUR Therapeutics Cancer mTOR Inhibitors Product and Services
Table 50. PIQUR Therapeutics Cancer mTOR Inhibitors Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 51. Semafore Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 52. Semafore Pharmaceuticals Major Business
Table 53. Semafore Pharmaceuticals Cancer mTOR Inhibitors Product and Services
Table 54. Semafore Pharmaceuticals Cancer mTOR Inhibitors Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 55. Takeda Basic Information, Manufacturing Base and Competitors
Table 56. Takeda Major Business
Table 57. Takeda Cancer mTOR Inhibitors Product and Services
Table 58. Takeda Cancer mTOR Inhibitors Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 59. Wyeth Basic Information, Manufacturing Base and Competitors
Table 60. Wyeth Major Business
Table 61. Wyeth Cancer mTOR Inhibitors Product and Services
Table 62. Wyeth Cancer mTOR Inhibitors Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 63. Global Cancer mTOR Inhibitors Sales by Manufacturer (2019-2021e) & (K Pcs)
Table 64. Global Cancer mTOR Inhibitors Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 65. Market Position of Manufacturers in Cancer mTOR Inhibitors, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 66. Global Cancer mTOR Inhibitors Production Capacity by Company, (K Pcs): 2020 VS 2021
Table 67. Head Office and Cancer mTOR Inhibitors Production Site of Key Manufacturer
Table 68. Cancer mTOR Inhibitors New Entrant and Capacity Expansion Plans
Table 69. Cancer mTOR Inhibitors Mergers & Acquisitions in the Past Five Years
Table 70. Global Cancer mTOR Inhibitors Sales by Region (2016-2021e) & (K Pcs)
Table 71. Global Cancer mTOR Inhibitors Sales by Region (2021-2026) & (K Pcs)
Table 72. Global Cancer mTOR Inhibitors Revenue by Region (2016-2021e) & (USD Million)
Table 73. Global Cancer mTOR Inhibitors Revenue by Region (2021-2026) & (USD Million)
Table 74. Global Cancer mTOR Inhibitors Sales by Type (2016-2021e) & (K Pcs)
Table 75. Global Cancer mTOR Inhibitors Sales by Type (2021-2026) & (K Pcs)
Table 76. Global Cancer mTOR Inhibitors Revenue by Type (2016-2021e) & (USD Million)
Table 77. Global Cancer mTOR Inhibitors Revenue by Type (2021-2026) & (USD Million)
Table 78. Global Cancer mTOR Inhibitors Price by Type (2016-2021e) & (USD/Pcs)
Table 79. Global Cancer mTOR Inhibitors Price by Type (2021-2026) & (USD/Pcs)
Table 80. Global Cancer mTOR Inhibitors Sales by Application (2016-2021e) & (K Pcs)
Table 81. Global Cancer mTOR Inhibitors Sales by Application (2021-2026) & (K Pcs)
Table 82. Global Cancer mTOR Inhibitors Revenue by Application (2016-2021e) & (USD Million)
Table 83. Global Cancer mTOR Inhibitors Revenue by Application (2021-2026) & (USD Million)
Table 84. Global Cancer mTOR Inhibitors Price by Application (2016-2021e) & (USD/Pcs)
Table 85. Global Cancer mTOR Inhibitors Price by Application (2021-2026) & (USD/Pcs)
Table 86. North America Cancer mTOR Inhibitors Sales by Country (2016-2021e) & (K Pcs)
Table 87. North America Cancer mTOR Inhibitors Sales by Country (2021-2026) & (K Pcs)
Table 88. North America Cancer mTOR Inhibitors Revenue by Country (2016-2021e) & (USD Million)
Table 89. North America Cancer mTOR Inhibitors Revenue by Country (2021-2026) & (USD Million)
Table 90. North America Cancer mTOR Inhibitors Sales by Type (2016-2021e) & (K Pcs)
Table 91. North America Cancer mTOR Inhibitors Sales by Type (2021-2026) & (K Pcs)
Table 92. North America Cancer mTOR Inhibitors Sales by Application (2016-2021e) & (K Pcs)
Table 93. North America Cancer mTOR Inhibitors Sales by Application (2021-2026) & (K Pcs)
Table 94. Europe Cancer mTOR Inhibitors Sales by Country (2016-2021e) & (K Pcs)
Table 95. Europe Cancer mTOR Inhibitors Sales by Country (2021-2026) & (K Pcs)
Table 96. Europe Cancer mTOR Inhibitors Revenue by Country (2016-2021e) & (USD Million)
Table 97. Europe Cancer mTOR Inhibitors Revenue by Country (2021-2026) & (USD Million)
Table 98. Europe Cancer mTOR Inhibitors Sales by Type (2016-2021e) & (K Pcs)
Table 99. Europe Cancer mTOR Inhibitors Sales by Type (2021-2026) & (K Pcs)
Table 100. Europe Cancer mTOR Inhibitors Sales by Application (2016-2021e) & (K Pcs)
Table 101. Europe Cancer mTOR Inhibitors Sales by Application (2021-2026) & (K Pcs)
Table 102. Asia-Pacific Cancer mTOR Inhibitors Sales by Region (2016-2021e) & (K Pcs)
Table 103. Asia-Pacific Cancer mTOR Inhibitors Sales by Region (2021-2026) & (K Pcs)
Table 104. Asia-Pacific Cancer mTOR Inhibitors Revenue by Region (2016-2021e) & (USD Million)
Table 105. Asia-Pacific Cancer mTOR Inhibitors Revenue by Region (2021-2026) & (USD Million)
Table 106. Asia-Pacific Cancer mTOR Inhibitors Sales by Type (2016-2021e) & (K Pcs)
Table 107. Asia-Pacific Cancer mTOR Inhibitors Sales by Type (2021-2026) & (K Pcs)
Table 108. Asia-Pacific Cancer mTOR Inhibitors Sales by Application (2016-2021e) & (K Pcs)
Table 109. Asia-Pacific Cancer mTOR Inhibitors Sales by Application (2021-2026) & (K Pcs)
Table 110. South America Cancer mTOR Inhibitors Sales by Country (2016-2021e) & (K Pcs)
Table 111. South America Cancer mTOR Inhibitors Sales by Country (2021-2026) & (K Pcs)
Table 112. South America Cancer mTOR Inhibitors Revenue by Country (2016-2021e) & (USD Million)
Table 113. South America Cancer mTOR Inhibitors Revenue by Country (2021-2026) & (USD Million)
Table 114. South America Cancer mTOR Inhibitors Sales by Type (2016-2021e) & (K Pcs)
Table 115. South America Cancer mTOR Inhibitors Sales by Type (2021-2026) & (K Pcs)
Table 116. South America Cancer mTOR Inhibitors Sales by Application (2016-2021e) & (K Pcs)
Table 117. South America Cancer mTOR Inhibitors Sales by Application (2021-2026) & (K Pcs)
Table 118. Middle East & Africa Cancer mTOR Inhibitors Sales by Country (2016-2021e) & (K Pcs)
Table 119. Middle East & Africa Cancer mTOR Inhibitors Sales by Country (2021-2026) & (K Pcs)
Table 120. Middle East & Africa Cancer mTOR Inhibitors Revenue by Country (2016-2021e) & (USD Million)
Table 121. Middle East & Africa Cancer mTOR Inhibitors Revenue by Country (2021-2026) & (USD Million)
Table 122. Middle East & Africa Cancer mTOR Inhibitors Sales by Type (2016-2021e) & (K Pcs)
Table 123. Middle East & Africa Cancer mTOR Inhibitors Sales by Type (2021-2026) & (K Pcs)
Table 124. Middle East & Africa Cancer mTOR Inhibitors Sales by Application (2016-2021e) & (K Pcs)
Table 125. Middle East & Africa Cancer mTOR Inhibitors Sales by Application (2021-2026) & (K Pcs)
Table 126. Direct Channel Pros & Cons
Table 127. Indirect Channel Pros & Cons
Table 128. Cancer mTOR Inhibitors Typical Distributors
Table 129. Cancer mTOR Inhibitors Typical Customers
List of Figures
Figure 1. Cancer mTOR Inhibitors Picture
Figure 2. Global Cancer mTOR Inhibitors Sales Market Share by Type in 2020
Figure 3. Afinitor/Votubia
Figure 4. Afinitor Disperz and ndash; mTOR inhibitor for Rare Pediatric Brain Tumor
Figure 5. Torisel (Temsirolimus)
Figure 6. Evertor andndash
Figure 7. Global Cancer mTOR Inhibitors Sales Market Share by Application in 2020
Figure 8. Breast Cancer
Figure 9. Hematological Malignancy
Figure 10. Neuroendocrine Tumors
Figure 11. Hepatocellular Carcinoma
Figure 12. Glioblastoma
Figure 13. Global Cancer mTOR Inhibitors Market Size, (USD Million) & (K Pcs): 2020 VS 2021 VS 2026
Figure 14. Global Cancer mTOR Inhibitors Market Size and Forecast (2016-2026) & (USD Million)
Figure 15. Global Cancer mTOR Inhibitors Sales (2016-2026) & (K Pcs)
Figure 16. Global Cancer mTOR Inhibitors Price by Type (2016-2026) & (USD/Pcs)
Figure 17. Global Cancer mTOR Inhibitors Production Capacity (2016-2026) & (K Pcs)
Figure 18. Global Cancer mTOR Inhibitors Production Capacity by Geographic Region: 2020 VS 2021
Figure 19. Cancer mTOR Inhibitors Market Drivers
Figure 20. Cancer mTOR Inhibitors Market Restraints
Figure 21. Cancer mTOR Inhibitors Market Trends
Figure 22. Global Cancer mTOR Inhibitors Sales Market Share by Manufacturer in 2020
Figure 23. Global Cancer mTOR Inhibitors Revenue Market Share by Manufacturer in 2020
Figure 24. Cancer mTOR Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 25. Top 3 Cancer mTOR Inhibitors Manufacturer (Revenue) Market Share in 2020
Figure 26. Top 6 Cancer mTOR Inhibitors Manufacturer (Revenue) Market Share in 2020
Figure 27. Global Cancer mTOR Inhibitors Sales Market Share by Region (2016-2026)
Figure 28. Global Cancer mTOR Inhibitors Revenue Market Share by Region (2016-2026)
Figure 29. North America Cancer mTOR Inhibitors Revenue (2016-2026) & (USD Million)
Figure 30. Europe Cancer mTOR Inhibitors Revenue (2016-2026) & (USD Million)
Figure 31. Asia-Pacific Cancer mTOR Inhibitors Revenue (2016-2026) & (USD Million)
Figure 32. South America Cancer mTOR Inhibitors Revenue (2016-2026) & (USD Million)
Figure 33. Middle East & Africa Cancer mTOR Inhibitors Revenue (2016-2026) & (USD Million)
Figure 34. Global Cancer mTOR Inhibitors Sales Market Share by Type (2016-2026)
Figure 35. Global Cancer mTOR Inhibitors Revenue Market Share by Type (2016-2026)
Figure 36. Global Cancer mTOR Inhibitors Price by Type (2016-2026) & (USD/Pcs)
Figure 37. Global Cancer mTOR Inhibitors Sales Market Share by Application (2016-2026)
Figure 38. Global Cancer mTOR Inhibitors Revenue Market Share by Application (2016-2026)
Figure 39. Global Cancer mTOR Inhibitors Price by Application (2016-2026) & (USD/Pcs)
Figure 40. North America Cancer mTOR Inhibitors Sales Market Share by Type (2016-2026)
Figure 41. North America Cancer mTOR Inhibitors Sales Market Share by Application (2016-2026)
Figure 42. North America Cancer mTOR Inhibitors Sales Market Share by Country (2016-2026)
Figure 43. North America Cancer mTOR Inhibitors Revenue Market Share by Country (2016-2026)
Figure 44. United States Cancer mTOR Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Canada Cancer mTOR Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Mexico Cancer mTOR Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Europe Cancer mTOR Inhibitors Sales Market Share by Type (2016-2026)
Figure 48. Europe Cancer mTOR Inhibitors Sales Market Share by Application (2016-2026)
Figure 49. Europe Cancer mTOR Inhibitors Sales Market Share by Country (2016-2026)
Figure 50. Europe Cancer mTOR Inhibitors Revenue Market Share by Country (2016-2026)
Figure 51. Germany Cancer mTOR Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. France Cancer mTOR Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. United Kingdom Cancer mTOR Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Russia Cancer mTOR Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Italy Cancer mTOR Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Asia-Pacific Cancer mTOR Inhibitors Sales Market Share by Region (2016-2026)
Figure 57. Asia-Pacific Cancer mTOR Inhibitors Sales Market Share by Application (2016-2026)
Figure 58. Asia-Pacific Cancer mTOR Inhibitors Sales Market Share by Region (2016-2026)
Figure 59. Asia-Pacific Cancer mTOR Inhibitors Revenue Market Share by Region (2016-2026)
Figure 60. China Cancer mTOR Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Japan Cancer mTOR Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Korea Cancer mTOR Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. India Cancer mTOR Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Southeast Asia Cancer mTOR Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Australia Cancer mTOR Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. South America Cancer mTOR Inhibitors Sales Market Share by Type (2016-2026)
Figure 67. South America Cancer mTOR Inhibitors Sales Market Share by Application (2016-2026)
Figure 68. South America Cancer mTOR Inhibitors Sales Market Share by Country (2016-2026)
Figure 69. South America Cancer mTOR Inhibitors Revenue Market Share by Country (2016-2026)
Figure 70. Brazil Cancer mTOR Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Argentina Cancer mTOR Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Middle East & Africa Cancer mTOR Inhibitors Sales Market Share by Type (2016-2026)
Figure 73. Middle East & Africa Cancer mTOR Inhibitors Sales Market Share by Application (2016-2026)
Figure 74. Middle East & Africa Cancer mTOR Inhibitors Sales Market Share by Country (2016-2026)
Figure 75. Middle East & Africa Cancer mTOR Inhibitors Revenue Market Share by Country (2016-2026)
Figure 76. Turkey Cancer mTOR Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Egypt Cancer mTOR Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Saudi Arabia Cancer mTOR Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. South Africa Cancer mTOR Inhibitors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
Figure 81. Methodology
Figure 82. Research Process and Data Source
世界の乳がん用PI3K/AKT/mTor経路阻害剤市場 2021：企業別、地域別、種類・用途別 The PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain …- 世界の乳がん用CDK4/6阻害薬市場 2021：企業別、地域別、種類・用途別 The CDK4/6 Inhibitors for Breast Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, t…
- 世界のがん用PARP阻害剤市場 2021：企業別、地域別、種類・用途別 The PARP Inhibitors for Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regu…
- 世界の乳がん用アロマターゼ阻害剤市場 2021：企業別、地域別、種類・用途別 The Aromatase Inhibitors for Breast Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization…
- 世界のがんチューブリン阻害剤市場 2021：企業別、地域別、種類・用途別 The Cancer Tubulin Inhibitors market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regul…